|
|
|
|
|
|
|
|
selected abstracts
Abstract 1 – Lessons From the Cancer Genome Atlas
D. Neil Hayes, University of North Carolina (UNC) School of Medicine, UNC Lineberger, Chapel Hill, North Carolina, USA
The past 5 years have seen an explosion of
data from cancer genome sequencing projects. The single largest
endeavor is the
Cancer Genome Atlas (TCGA). As of the beginning of
2015, TCGA had deposited more than 11,000 patient genome profiles into
the public record, covering more than 30 tumor
types. The experience gained by TCGA offers insights into future
translational
research in the era of genomics. Lessons learned
from the analysis of these 11,000 patients will direct researchers and
clinicians
alike. The goal of this talk is to summarize the
TCGA experience and to look forward to next steps in genomics research,
clinical
trials, and clinical care.
Abstract 3 – Functional Genomics and Proteomics of Ovarian Cancer Elucidate Novel Targets and Therapies
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, Texas USA
Ovarian cancer is a disease of copy number
change, with few recurrent genomic mutations other than almost
universal changes
in TP53 and abnormalities in BRCA1/2 in the
pathways regulated by BRCA1/2. A number of drugs are emerging that can
normalize
the function of a subset of TP53 mutations, and
additional drugs, such as WEE1 inhibitors, may exert greater activity in
TP53-mutant
tumors. The most exciting opportunity in ovarian
cancer therapy is the emergence of poly(ADP ribose) polymerase (PARP)
inhibitors
as synthetic lethal drugs with abnormalities in
BRCA1/2 defects. Furthermore, it is critically important to identify
markers
of benefits and rational drug combinations for
patients receiving PARP inhibitors. Finally, it is unlikely that
monotherapy
will have major impact on patients with ovarian
cancer because of its complex genomic nature. Thus, it will be critical
to
identify rational drug combinations. Approaches to
each of these opportunities and challenges will be presented.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.